moviprep pulver til oral opløsning
norgine b.v. - ascorbinsyre, kaliumchlorid, macrogol 3350, natriumascorbat, natriumchlorid, natriumsulfat, vandfrit - pulver til oral opløsning
neurontin 300 mg kapsler, hårde
upjohn eesv - gabapentin - kapsler, hårde - 300 mg
neurontin 400 mg kapsler, hårde
upjohn eesv - gabapentin - kapsler, hårde - 400 mg
nuvaring 120+15 mikg/24 timer vaginalindlæg
n.v. organon - ethinylestradiol, etonogestrel - vaginalindlæg - 120+15 mikg/24 timer
onytec 80 mg/g medicinsk neglelak
polichem sa - ciclopirox - medicinsk neglelak - 80 mg/g
sevofluran "baxter" 1 ml/ml væske til inhalationsdamp
baxter a/s - sevofluran - væske til inhalationsdamp - 1 ml/ml
zoloft 20 mg/ml koncentrat til oral opløsning
pfizer aps - sertralinhydrochlorid - koncentrat til oral opløsning - 20 mg/ml
innovair nexthaler 200+6 mikrog./dosis inhalationspulver
chiesi farmaceutici s.p.a. - beclometasondipropionat, formoterolfumarat dihydrat - inhalationspulver - 200+6 mikrog./dosis
pegasys
pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 og 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. med hensyn til beslutningen om at indlede behandling hos pædiatriske patienter, se afsnit 4. 2, 4. 4 og 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 og 5. for at hepatitis c virus (hcv) genotype specifik aktivitet, se afsnit 4. 2 og 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. når det besluttes at indlede behandling i barndommen, er det vigtigt at overveje, væksthæmning, der er fremkaldt af en kombination terapi. reversibilitet af væksthæmning er usikker. beslutningen om at behandling skal ske på grundlag af en individuel vurdering (se afsnit 4.
signum vanddispergerbart granulat
basf a/s - pyraclostrobin, boscalid - vanddispergerbart granulat - 67 g/kg pyraclostrobin ; 267 g/kg boscalid